Inbiomotion: Predicting bone metastasis

Sobre Inbiomotion

Inbiomotion is a Barcelona-based personalized medicine company incorporated in 2010 with the goal of developing biomarkers that predict bone metastasis to improve the quality of life of cancer patients. The company is a spin out of the IRB Barcelona and ICREA research institutions and was founded by Dr. Roger Gomis. Our activities are focused on the development of a diagnostic assay based on a selective single gene/protein biomarker that predicts those patients at risk of suffering bone-specific metastases from primary tumors. The exquisite selectivity of our lead biomarker provides the grounds for the development of companion diagnostics – selecting patients that will benefit from the preventive use of anti-bone metastatic drugs, and making a step forward in the clinical standard of care using personalized medicine.

Datos Inbiomotion

Total inversión 1.520.000€
Rondas inversión
  • Early/Startup
    2.500,00 K€

Equipo Inbiomotion 1

Inversores Inbiomotion 1

Acceleradoras Inbiomotion 0

Noticias Inbiomotion 0